Showing results (161-170 of 175) with videos related to
Sort By:
Pageof 18
International Journal of Clinical Oncology|April 5, 2024
Effectiveness of G-CSF in chemotherapy for digestive system tumors: a systematic review of the Clinical Practice Guidelines for the Use of G-CSF 2022 delineated by the Japan Society of Clinical OncologyMamoru Ito, Yuta Okumura, Kenta Nio, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2024
Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, <i>EGFR</i>-Mutant, Metastatic Nonsquamous Non-Small Cell Lung CancerJames Chih-Hsin Yang, Dae Ho Lee, Jong-Seok Lee, et al.International Journal of Clinical Oncology|March 22, 2024
Effectiveness and safety of primary prophylaxis of granulocyte colony-stimulating factor during dose-dense chemotherapy for urothelial cancer: Clinical Practice Guidelines for the Use of G-CSF 2022Keita Uchino, Shingo Tamura, Shoji Kimura, et al.International Journal of Clinical Oncology|February 14, 2024
Effectiveness and safety of primary prophylaxis with G-CSF for lung cancer: a systematic review and meta-analysis to develop clinical practice guidelines for the use of G-CSF 2022Eiki Ichihara, Nobuaki Ochi, Go Makimoto, et al.International Journal of Clinical Oncology|March 28, 2024
Effectiveness and safety of primary prophylaxis of G-CSF during chemotherapy for prostate cancer, Japanese clinical guideline for appropriate use of G-CSF: clinical practice guidelines for the use of G-CSF 2022Shoji Kimura, Keisuke Shigeta, Shingo Tamura, et al.Nature Medicine|August 25, 2015
RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancerGorjan Hrustanovic, Victor Olivas, Evangelos Pazarentzos, et al.Cancer Research|April 15, 2015
Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical ModelsCatherine A Eberlein, Daniel Stetson, Aleksandra A Markovets, et al.Cancer Discovery|April 23, 2016
EGFR Fusions as Novel Therapeutic Targets in Lung CancerKartik Konduri, Jean-Nicolas Gallant, Young Kwang Chae, et al.Cancer Research Communications|March 16, 2023
Mixed Response to Cancer Immunotherapy is Driven by Intratumor Heterogeneity and Differential Interlesion Immune InfiltrationTakao Morinaga, Takashi Inozume, Masahito Kawazu, et al.Cancer Discovery|June 5, 2014
AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancerDarren A E Cross, Susan E Ashton, Serban Ghiorghiu, et al.Pageof 18